Coherus BioSciences, Inc. (NASDAQ:CHRS) Expected to Post Quarterly Sales of $114.90 Million


Share on StockTwits

Equities analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS) to report $114.90 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Coherus BioSciences’ earnings. The lowest sales estimate is $109.60 million and the highest is $118.16 million. Coherus BioSciences reported sales of $123.86 million during the same quarter last year, which would suggest a negative year over year growth rate of 7.2%. The company is expected to report its next earnings report on Thursday, February 25th.

According to Zacks, analysts expect that Coherus BioSciences will report full-year sales of $480.24 million for the current year, with estimates ranging from $475.00 million to $483.57 million. For the next fiscal year, analysts forecast that the business will report sales of $455.98 million, with estimates ranging from $427.41 million to $494.99 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Coherus BioSciences.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.01). The firm had revenue of $113.55 million for the quarter, compared to analyst estimates of $120.50 million. Coherus BioSciences had a return on equity of 90.98% and a net margin of 33.06%.

CHRS has been the topic of a number of recent research reports. BidaskClub raised shares of Coherus BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, January 9th. Zacks Investment Research cut shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Monday, January 4th. Mizuho lowered their price target on Coherus BioSciences from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, November 19th. Finally, HC Wainwright reduced their price objective on Coherus BioSciences from $33.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Coherus BioSciences currently has a consensus rating of “Hold” and a consensus price target of $28.25.

In other news, COO Vincent R. Anicetti sold 49,756 shares of the stock in a transaction that occurred on Thursday, December 3rd. The stock was sold at an average price of $18.67, for a total transaction of $928,944.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jean-Frederic Viret sold 1,995 shares of Coherus BioSciences stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $17.49, for a total transaction of $34,892.55. The disclosure for this sale can be found here. Insiders sold a total of 82,451 shares of company stock valued at $1,521,011 over the last quarter. Company insiders own 15.86% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Thrivent Financial for Lutherans raised its position in Coherus BioSciences by 2.2% in the third quarter. Thrivent Financial for Lutherans now owns 52,150 shares of the biotechnology company’s stock worth $956,000 after acquiring an additional 1,104 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Coherus BioSciences by 2.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 58,840 shares of the biotechnology company’s stock worth $1,079,000 after purchasing an additional 1,310 shares in the last quarter. Comerica Bank lifted its stake in Coherus BioSciences by 2.1% during the third quarter. Comerica Bank now owns 65,653 shares of the biotechnology company’s stock valued at $1,155,000 after purchasing an additional 1,368 shares during the last quarter. Globeflex Capital L P boosted its holdings in Coherus BioSciences by 5.6% during the third quarter. Globeflex Capital L P now owns 28,890 shares of the biotechnology company’s stock worth $530,000 after buying an additional 1,521 shares in the last quarter. Finally, DNB Asset Management AS grew its position in Coherus BioSciences by 9.1% in the third quarter. DNB Asset Management AS now owns 19,443 shares of the biotechnology company’s stock worth $357,000 after buying an additional 1,626 shares during the last quarter.

CHRS opened at $17.24 on Thursday. Coherus BioSciences has a 1 year low of $10.86 and a 1 year high of $23.03. The firm has a 50 day moving average price of $17.82 and a 200 day moving average price of $18.14. The company has a debt-to-equity ratio of 1.58, a quick ratio of 5.18 and a current ratio of 5.45. The company has a market cap of $1.24 billion, a PE ratio of 8.45, a price-to-earnings-growth ratio of 9.58 and a beta of 1.57.

About Coherus BioSciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Article: Gap Up Stocks

Get a free copy of the Zacks research report on Coherus BioSciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.